Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Raw Materials: 2022-2024

Historic Raw Materials for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $9.5 million.

  • Axsome Therapeutics' Raw Materials rose 60.49% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 60.49%. This contributed to the annual value of $9.5 million for FY2024, which is 72.41% up from last year.
  • According to the latest figures from FY2024, Axsome Therapeutics' Raw Materials is $9.5 million, which was up 72.41% from $5.5 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Raw Materials registered a high of $9.5 million during FY2024, and its lowest value of $2.5 million during FY2022.
  • For the 3-year period, Axsome Therapeutics' Raw Materials averaged around $5.8 million, with its median value being $5.5 million (2023).
  • Data for Axsome Therapeutics' Raw Materials shows a peak YoY spiked of 123.78% (in 2023) over the last 5 years.
  • Over the past 3 years, Axsome Therapeutics' Raw Materials (Yearly) stood at $2.5 million in 2022, then spiked by 123.78% to $5.5 million in 2023, then spiked by 72.41% to $9.5 million in 2024.